Antiplatelet Conversion - P2Y12 Inhibitor Switching
 • Clopidogrel (Plavix)
 • Prasugrel (Effient)
 • Ticagrelor (Brilinta)
Clopidogrel and prasugrel are both competitive antagonists that bind to the active site of the P2Y12 receptor.  Ticagrelor, a noncompetitive antagonist, binds to the allosteric site, causing a conformational change in the active site and thus preventing the binding of clopidogrel and prasugrel
 • Irreversible inhibitor: clopidogrel and prasugrel
 • Reversible inhibitor: ticagrelor

by Dr. Laila Najia @laila_najia via ACCP Cardiology PRN @accpcardprn

#Antiplatelet #Conversion #P2Y12 #Inhibitor #Switching #pharmacology #cardiology